Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope

Abstract

Biopharmaceuticals, monoclonal antibody (mAb)-based therapeutics in particular, have positively impacted millions of lives. MAbs and related therapeutics are highly desirable from a biopharmaceutical perspective as they are highly target specific and well tolerated within the human system. Nevertheless, several mAbs have been discontinued or withdrawn based either on their inability to demonstrate efficacy and/or due to adverse effects. Approved monoclonal antibodies and derived therapeutics have been associated with adverse effects such as immunogenicity, cytokine release syndrome, progressive multifocal leukoencephalopathy, intravascular haemolysis, cardiac arrhythmias, abnormal liver function, gastrointestinal perforation, bronchospasm, intraocular inflammation, urticaria, nephritis, neuropathy, birth defects, fever and cough to name a few. The advances made in this field are also impeded by a lack of progress in bioprocess development strategies as well as increasing costs owing to attrition, wherein the lack of efficacy and safety accounts for nearly 60 % of all factors contributing to attrition. This reiterates the need for smarter preclinical development using quality by design-based approaches encompassing carefully designed predictive models during early stages of drug development. Different in vitro and in silico methods are extensively used for predicting biological activity as well as toxicity during small molecule drug development; however, their full potential has not been utilized for biological drug development. The scope of in vitro and in silico tools in early developmental stages of monoclonal antibody-based therapeutics production and how it contributes to lower attrition rates leading to faster development of potential drug candidates has been evaluated. The applicability of computational toxicology approaches in this context as well as the pitfalls and promises of extending such techniques to biopharmaceutical development has been highlighted.Electronic supplementary materialThe online version of this article (doi:10.1007/s00204-016-1876-7) contains supplementary material, which is available to authorized users.

Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism

“…Monoclonal antibodies Adverse effects including acute anaphylaxis, serum sickness, cardiotoxicity etc. Hansel et al, 2010;Kizhedath et al, 2016 Increase chance of fungal infections with anti-TNFα monoclonal antibodies.…”

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

“…However, many of these are being used for small molecules, often to assess off-target toxicity, rather than for the screening of biotherapeutics 22 . One reason might be that such technologies are not relevant for mAb development because off-target toxicity rarely occurs and the toxicity is primarily related to specific on-target pharmacology.…”

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

“…Cardiotoxicity caused by these novel agents or modalities are diverse, and many specific mechanisms of individual compounds or modalities underlying this toxicity remain to be elucidated . Some commonly conceptualized mechanisms underlie toxicity, including on‐ and off‐target toxicity, production of toxic metabolites, harmful immune responses, unpredictable specificities of targeted tumor antigens, tumor lysis symptoms, cytokine release syndrome, T‐cell receptor (TCR) mispairing, TCR cross‐reactivity, and idiosyncratic mechanisms …”

“…Unfortunately, the newer targeted agents or modalities exhibit a similar frequency and severity of toxicities as traditional cytotoxic agents do, albeit with differences in preference for the organs/tissues that are involved . Many unanticipated short‐ and long‐term adverse effects on multiple organs/tissues have shown the limitations of the new therapies, although MTTs have improved the overall survival of cancer patients over the past two decades, and advanced immunotherapies are promising to improve the outcomes of certain types of cancers (ICIs and CART). Cardiac complications associated with cancer treatment represent unresolved and potentially life‐threatening conditions in cancer survivors.…”

“…50Some commonly conceptualized mechanisms underlie toxicity, including on-and off-target toxicity, production of toxic metabolites, harmful immune responses, unpredictable specificities of targeted tumor antigens, tumor lysis symptoms, cytokine release syndrome, T-cell receptor (TCR) mispairing, TCR cross-reactivity, and idiosyncratic mechanisms. [51][52][53][54][55][56] A primary goal of targeted therapy or more advanced immune-based modalities is to kill cancer cells more specifically than traditional treatment modalities while maintaining an acceptable level of side effects and quality of life.Unfortunately, the newer targeted agents or modalities exhibit a similar frequency and severity of toxicities as traditional cytotoxic agents do, albeit with differences in preference for the organs/tissues that are involved. 57 Many unanticipated short-and long-term adverse effects on multiple organs/tissues have shown the limitations of the new therapies, 7,30,56-59 although MTTs have improved the overall survival of cancer patients over the past two decades, 57,60,61 and advanced immunotherapies are promising to improve the outcomes of certain types of cancers (ICIs 62-70 and CART 71-74 ).…”